Does Enovis ( ENOV ) Have the Potential to Rally 77.33% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 77.3% in Enovis (ENOV). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Enovis to Participate in Upcoming Investor Conferences
Wilmington, DE, Aug. 08, 2025 ( GLOBE NEWSWIRE ) -- Enovis™ Corporation ( NYSE: ENOV ) , an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences: ...
Enovis to Participate in Upcoming Investor Conferences - Enovis ( NYSE:ENOV )
Wilmington, DE, Aug. 08, 2025 ( GLOBE NEWSWIRE ) -- Enovis™ Corporation ENOV, an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences: Canaccord Genuity 45th Annual Growth Conference on Wednesday, ...
Enovis ( ENOV ) Q2 Revenue Rises 7%
Enovis ( NYSE:ENOV ) , a medical technology company focused on orthopedics and recovery products, announced results for Q2 2025 on August 7, 2025. The headline news was a clear beat on both GAAP revenue and non-GAAP adjusted earnings per share.
Enovis ( ENOV ) Beats Q2 Earnings and Revenue Estimates
Enovis (ENOV) delivered earnings and revenue surprises of +6.76% and +1.83%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Enovis Announces Second Quarter 2025 Results
Wilmington, DE, Aug. 07, 2025 ( GLOBE NEWSWIRE ) -- Enovis™ Corporation ( "Enovis" or "the Company" ) ( NYSE: ENOV ) , an innovation-driven medical technology growth company, today announced its financial results for the second quarter ended July 4, 2025.
Enovis to Host Second Quarter 2025 Results Conference Call on August 7th - Enovis ( NYSE:ENOV )
Wilmington, DE, July 08, 2025 ( GLOBE NEWSWIRE ) -- Enovis™ Corporation ENOV, an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its second quarter 2025 financial results on Thursday, August 7th, 2025, at ...
Enovis to Participate in Upcoming Investor Conferences
Wilmington, DE, June 06, 2025 ( GLOBE NEWSWIRE ) -- Enovis™ Corporation ( NYSE: ENOV ) , an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences: ...
Enovis to Participate in Upcoming Investor Conferences - Enovis ( NYSE:ENOV )
Wilmington, DE, June 06, 2025 ( GLOBE NEWSWIRE ) -- Enovis™ Corporation ENOV, an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences:
Enovis ( ENOV ) Q1 Earnings and Revenues Surpass Estimates
Enovis (ENOV) delivered earnings and revenue surprises of 9.46% and 0.03%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Enovis Announces First Quarter 2025 Results
• Continued commercial momentum with first-quarter sales growth of 8% on a reported basis and strong adjusted EBITDA margin expansion
Are Options Traders Betting on a Big Move in Enovis ( ENOV ) Stock?
Investors need to pay close attention to Enovis (ENOV) stock based on the movements in the options market lately.
Enovis to Host First Quarter 2025 Results Conference Call on May 8th
Wilimington, DE, April 17, 2025 ( GLOBE NEWSWIRE ) -- Enovis™ Corporation ( NYSE: ENOV ) , an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its first quarter 2025 financial results on Thursday, May 8th, ...
Enovis Announces Appointment of Damien McDonald as Chief Executive Officer
WIlmington. DE, April 02, 2025 ( GLOBE NEWSWIRE ) -- Enovis™ Corporation ( "Enovis" or "The Company" ) ( NYSE: ENOV ) , a leader in medical technology innovation, today announced the appointment of Damien McDonald as Chief Executive Officer, effective May 12, 2025.
Bone Cement Market Sales on Track for US$ 1.2 Billion by 2035, Expanding at 5.2% CAGR with Rising Demand for Orthopedic Surgeries - Analysis by Transparency Market Research
Wilmington, Delaware, Transparency Market Research, Inc. -, March 17, 2025 ( GLOBE NEWSWIRE ) -- Rising orthopedic procedures and advancements in biomaterials are driving market growth. The Global Bone Cement Market Size was valued at US$ 657.8 Million in 2024 and is projected to expand at a 5.2% ...
Nailing Systems Market is expected to generate a revenue of USD 654.49 Million by 2032, Globally, at 5.4% CAGR: Verified Market Research®
Lewes, Delaware, March 11, 2025 ( GLOBE NEWSWIRE ) -- The Global Nailing Systems Market Size is projected to grow at a CAGR of 5.4% from 2026 to 2032, according to a new report published by Verified Market Research®.
Enovis ( ENOV ) Q4 Earnings and Revenues Surpass Estimates
Enovis (ENOV) delivered earnings and revenue surprises of 6.52% and 0.84%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Enovis Announces Fourth Quarter and Full Year 2024 Results
Wilmington, DE, Feb. 26, 2025 ( GLOBE NEWSWIRE ) -- Enovis™ Corporation ( "Enovis" or "the Company" ) ( NYSE: ENOV ) , an innovation-driven medical technology growth company, today announced its financial results for the fourth quarter and full year ended December 31, 2024.
Enovis Announces Planned CEO Succession Process
Wilmington, DE, Feb. 26, 2025 ( GLOBE NEWSWIRE ) -- Enovis™ Corporation ( "Enovis" or "the Company" ) ( NYSE: ENOV ) , a leader in medical technology innovation, announced today that Matt Trerotola has informed the Board of Directors ( the "Board" ) of his intention to retire from his position ...
Talkspace, Inc. ( TALK ) Q4 Earnings Meet Estimates
Talkspace (TALK) delivered earnings and revenue surprises of 0% and 3.35%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
10x Genomics ( TXG ) Reports Q4 Loss, Tops Revenue Estimates
10x Genomics (TXG) delivered earnings and revenue surprises of -25% and 0.03%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Enovis to Host Fourth Quarter and Full Year 2024 Results Conference Call on February 26th - Enovis ( NYSE:ENOV )
Wilmington, DE, Jan. 29, 2025 ( GLOBE NEWSWIRE ) -- Enovis™ Corporation ENOV, an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its fourth quarter and full year 2024 financial results on Wednesday, ...
Zacks Industry Outlook Enovis, Omnicell and Phreesia
Enovis, Omnicell and Phreesia have been highlighted in this Industry Outlook article.
3 Medical Info Systems Stocks to Buy as Stargate AI Drives Industry Prospects
Zacks Medical Info Systems industry stocks like Enovis, Omnicell and Phreesia are expected to gain from the GenAI wave.
Osteotec announces exclusive partnership with Highridge Medical to distribute spine surgery solutions in the UK
NEWBURY, England, Jan. 21, 2025 /PRNewswire/ -- Osteotec, the market leading manufacturer and distributor of specialised medical devices, is pleased to announce an exclusive distribution agreement with Highridge Medical.
Centene Expands Care in Hawaii With a Residential Program
CNC's 'Ohana Health Plan joins forces with Hope Services Hawaii to launch a residential program offering integrated clinical care for members facing homelessness and complex health needs.
Company News for Jan 10, 2025
Companies In The News Are: EIX, CEG, EBAY, META, CART, ENOV.
Instacart Grows Stronger: S&P MidCap 400 Inclusion, Ulta Partnership Boosts Stock - Maplebear ( NASDAQ:CART )
Instacart ( CART ) joins S&P MidCap 400, replacing Enovis, boosting stock after a 91% annual gain. Instacart partners with Ulta Beauty for same-day delivery, enhancing customer convenience and expanding their product offerings. Get Monthly Picks of Market's Fastest Movers Maplebear Inc.
Here's Why Investors Should Retain Molina Healthcare Stock for Now
MOH remains well-poised for growth, attributable to improved premium revenues, buyouts and an aging U.S. population.
Enovis to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Wilmington, DE, Jan. 06, 2025 ( GLOBE NEWSWIRE ) -- Enovis™ Corporation ( NYSE: ENOV ) , an innovation-driven, medical technology growth company, today announced that its management team will meet with investors at the 43nd Annual J.P.
Osteotec appointed as exclusive distributor for Cerapedics in the UK and Ireland
NEWBURY, England, Dec. 11, 2024 /PRNewswire/ -- Osteotec, the market leading manufacturer and distributor of specialised medical devices, is pleased to announce an exclusive agreement to distribute Cerapedics' clinically proven i-FACTOR bone graft portfolio in the UK and Ireland.
Brady Corporation elects Board of Directors and declares regular dividend to shareholders - Brady ( NYSE:BRC )
MILWAUKEE, Dec. 04, 2024 ( GLOBE NEWSWIRE ) -- Brady Corporation BRC ( "Company" ) announced that shareholders of the Company's Class B Common Voting Stock have voted unanimously in favor of the election of the director nominees to a one-year term at the Company's annual meeting of shareholders ...
Treace Appoints Guy Guglielmino as Chief Commercial Officer
PONTE VEDRA, Fla., Dec. 02, 2024 ( GLOBE NEWSWIRE ) -- Treace Medical Concepts, Inc. ( "Treace" or the "Company" ) ( NasdaqGS: TMCI ) , a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® ...
Treace Appoints Guy Guglielmino as Chief Commercial Officer - Treace Medical Concepts ( NASDAQ:TMCI )
PONTE VEDRA, Fla., Dec. 02, 2024 ( GLOBE NEWSWIRE ) -- Treace Medical Concepts, Inc. ( "Treace" or the "Company" ) TMCI, a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and ...
Enovis to Participate in Upcoming Investor Conferences
Wilmington, DE, Nov. 18, 2024 ( GLOBE NEWSWIRE ) -- Enovis™ Corporation ( NYSE: ENOV ) , an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences: ...
Enovis to Participate in Upcoming Investor Conferences - Enovis ( NYSE:ENOV )
Wilmington, DE, Nov. 18, 2024 ( GLOBE NEWSWIRE ) -- Enovis™ Corporation ENOV, an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences:
Enovis ( ENOV ) Upgraded to Buy: Here's Why
Enovis (ENOV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Predict a 38.95% Upside in Enovis ( ENOV ) : Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 39% in Enovis (ENOV). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Enovis ( ENOV ) Q3 Earnings and Revenues Beat Estimates
Enovis (ENOV) delivered earnings and revenue surprises of 15.87% and 0.25%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Enovis Announces Third Quarter 2024 Results
Wilmington, DE, Nov. 06, 2024 ( GLOBE NEWSWIRE ) -- Enovis™ Corporation ( NYSE: ENOV ) , an innovation-driven medical technology growth company, today announced its financial results for the third quarter ended September 27, 2024. The Company will host an investor conference call and live webcast ...
Enovis to Host Third Quarter 2024 Results Conference Call on November 6th
Wilmington, DE, Oct. 10, 2024 ( GLOBE NEWSWIRE ) -- Enovis™ Corporation ( NYSE: ENOV ) , an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its third quarter 2024 financial results on Wednesday, November ...
Enovis to Host Third Quarter 2024 Results Conference Call on November 6th - Enovis ( NYSE:ENOV )
Wilmington, DE, Oct. 10, 2024 ( GLOBE NEWSWIRE ) -- Enovis™ Corporation ENOV, an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its third quarter 2024 financial results on Wednesday, November 6th, 2024 at ...
Orthopedic Implant Player Enovis' M&A Strategy Core To Growth And Competitiveness, Analyst Says - Enovis ( NYSE:ENOV )
JMP Securities initiated coverage on Enovis Corporation ENOV, a medical technology company focusing on orthopedics. The analyst adds that the company sells a broad portfolio of products, many of which were added via selective acquisitions ( around 20 over the last 4.5 years ) .
Enovis Appoints Tim Czartoski as President, U.S. Surgical and Global Product and Enabling Technologies
WILMINGTON, DE, Sept. 09, 2024 ( GLOBE NEWSWIRE ) -- Enovis™ ( NYSE: ENOV ) , an innovation-driven medical technology growth company, is pleased to announce the appointment of Tim Czartoski to the position of President, U.S. Surgical and Global Product and Enabling Technologies.
Enovis ( ENOV ) Introduces STAR Ankle With e+ Polyethylene
Enovis (ENOV) brings the first mobile-bearing ankle system with e+ Polyethylene, which offers enhanced durability, stability and longevity for improved patient outcomes.
Enovis Continues to Redefine Revision Knee Surgery with the Addition of EMPOWR™ Cones to EMPOWR Revision Knee™, Creating a Comprehensive Portfolio for Efficient Revision Procedures - Enovis ( NYSE:ENOV )
WILMINGTON, DE, Aug. 20, 2024 ( GLOBE NEWSWIRE ) -- Enovis™ ENOV, an innovation-driven medical technology growth company, announced today the expansion of its EMPOWR Revision Knee™ system to include EMPOWR™ Cones.
Enovis Continues to Redefine Revision Knee Surgery with the Addition of EMPOWR™ Cones to EMPOWR Revision Knee™, Creating a Comprehensive Portfolio for Efficient Revision Procedures
First surgeries using EMPOWR Revision Knee™ with EMPOWR™ Cones successfully completed by design consultants Dr. Beau Kildow and Dr. Leonard T. Buller. First surgeries using EMPOWR Revision Knee™ with EMPOWR™ Cones successfully completed by design consultants Dr. Beau Kildow and Dr. Leonard T.
Enovis™ Introduces STAR® Ankle, now with e+™ Polyethylene for Unmatched Durability - Enovis ( NYSE:ENOV )
Wilmington, DE, Aug. 19, 2024 ( GLOBE NEWSWIRE ) -- Enovis™ Corporation ENOV, an innovation-driven medical technology company, proudly unveils its Scandinavian Total Ankle Replacement ( STAR® Ankle ) , now with new e+™ Polyethylene. Recent U.S.
Varicose Veins Treatment Market to Attract Revenues Worth USD 2.4 Billion by 2031 at 4.8% CAGR - Report by Transparency Market Research Inc.
Wilmington, Delaware, United States, Transparency Market Research, Inc. , Aug. 19, 2024 ( GLOBE NEWSWIRE ) -- The varicose veins treatment market size ( 정맥류 치료 시장 ) is expected to reach US$ 2.4 Bn by the end of 2031 during the forecast period, as per Transparency Market Research ( TMR ) , a ...
Enovis to Participate in Upcoming Investor Conferences - Enovis ( NYSE:ENOV )
Wilmington, DE, Aug. 12, 2024 ( GLOBE NEWSWIRE ) -- Enovis™ Corporation ENOV, an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences:
